MedTrace Logo

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

NCT07713732 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-07-28

No results posted yet for this study

Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Conditions

  • Small Cell Lung Cancer ( SCLC )
  • Neuroendocrine Cancer
  • Malignant Pleural Mesotheliomas (Mpm)
  • Synovial Sarcomas

Interventions

DRUG

TLN-499

Specified dose on specified days

DRUG

Venetoclax

Specified dose on specified days

Sponsors & Collaborators

  • Treeline Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Padma Yerramilli-Rao, MB BS, PhD · Treeline Biosciences, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-25
Primary Completion
2030-08-29
Completion
2030-08-29

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07713732 on ClinicalTrials.gov